2007 PREVIEW: Great expectations - WatersTechnology.com

WatersTechnology Staff
01 Jan 2007

Tweet
Facebook
LinkedIn
Save this article
Send to
Print this page

Catherine Doherty, principal, Investit

OTC derivatives will continue to dominate the buy side's operational and technological priorities. Investment managers and outsourcers are developing long-term plans to support OTCs – firms are currently formalising OTC governance procedures. They are also prioritising OTC pricing and valuation data, collateral management and improved IT solutions to handle OTC complexity.

The MiFID requirement for best execution of OTCs will create a vigorous debate on

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to print this content. Please contact [email protected] to find out more.

You are currently unable to copy this content. Please contact [email protected] to find out more.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email [email protected]

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email [email protected]